Back on Our Radar With Breaking News: (Nasdaq: SXTP) Expands Babesiosis Trials to Brigham Hospital

*Sponsored by 60 Degrees Pharmaceuticals, Inc. Market Crux Exclusive! See Why 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is Back on Our Radar Today! There’s only around 1.5M shares in the float, setting the stage for significant swing potential if demand begins to shift. The CEO was recently purchasing shares, highlighting strong belief in the company’s future and growth prospects. A $3.40 analyst target suggests a 119% upside from  yesterday's $1.55 open. An approximate 182% move over the past six weeks signals  growing public interest. Over 40 patents, including three Orange Book-listed patents, provide market exclusivity and innovation strength. ARAKODA®, addressing a $50–$70M U.S. malaria market, is FDA-approved and commercially available. Pivotal trials for tick-borne diseases and chronic illnesses position the company in key emerging markets. December 11, 2024 Dear Reader, Yesterday, we highlighted 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) and their innovative approach to tackling severe babesiosis.  (SXTP) moved approximately 70% on the day. Today, they’re back in the headlines with major news: the expansion of their tafenoquine clinical trial to Brigham and Women’s Hospital in Boston. This double-blind, placebo-controlled study will evaluate tafenoquine in combination with standard care, targeting hospitalized patients suffering from this life-threatening tick-borne illness.  The trial is being conducted by distinguished researchers Dr. Ann Woolley and Dr. David Leaf, adding even more expertise to this critical effort. CEO Geoffrey Dow shared his thoughts on the collaboration: “We are pleased to be collaborating with Brigham and Women’s Hospital on finding answers to the question of how to bring a safe and effective new treatment option to people hospitalized with severe babesiosis, a potentially life-threatening tick-borne illness. In the near term, this collaboration promises to substantially enhance our ability to complete enrollment of this important clinical trial during the 2025 tick season. We look forward to a productive collaboration with the Hospital.” Babesiosis, often linked to Lyme disease, poses a rising public health threat, particularly in the Northeast U.S. Tafenoquine, already approved as ARAKODA® for malaria prophylaxis, is being tested for its ability to achieve faster recoveries and molecular cures for babesiosis patients. With recruitment planned for 2025 and interim results expected in 2026, the stakes are high.  The potential market is estimated at over 400,000 patients by the end of tafenoquine’s patent protection in 2035.  This trial could mark a turning point in the treatment of tick-borne diseases.  Take a look at the company;s press release here. If you missed our coverage on 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) yesterday you’re in luck. Because after its approximate 70% one day move it’s back on our radar this morning.  (SXTP) took center stage yesterday reaching $1.98 during the day session, but after hours was a different story.   By 4:40 PM EST, (SXTP) reached $2.65, surpassing almost every moving average Barchart tracks including: 5-Day: 1.3500 20-Day: 1.0776 50-Day: 1.0119 100-Day: 1.2846 200-Day: 2.2181 And actually, over the past week, (SXTP) moved approximately 157% from last Tuesday when it was in the $1.03 range. With (SXTP)’s 200-Day moving average now at 2.2181 we need to keep a very close eye on this. Keep reading to see why this one is back on our radar this morning. 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) comes backed by several potential catalysts including: Triggering 16 Bullish Signals on TradingView’s technical analysis tool.  An ultra-low float of only 1.5M shares, setting the stage for potential swings.  Analyst target suggests 119% potential upside target. An approximate 182% move in six weeks, could suggest the public is starting to catch on. Strong intellectual property portfolio with over 40 patents. Insider buying with the CEO picking up thousands of shares over the last few days: 12/05/2024 - 17,549 shares 12/06/2024 - 20,579 shares 12/09/2024 - 35,823 shares Building on its achievements in malaria prevention, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is now advancing efforts to tackle babesiosis, a tick-borne disease that is becoming increasingly prevalent in the U.S.  The company has initiated pivotal trials for acute babesiosis and is preparing to address chronic cases in the near future. With FDA orphan status granted to tafenoquine, the treatment shows promise as a leading option in a space where current therapies fall short.  Babesiosis presents both a pressing public health concern and a significant market opportunity, with up to 1 Mln chronic cases in the U.S. and rising acute incidence rates.  By targeting this underserved area, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is strategically positioning itself to potentially reach over 2 Mln patients. FDA-Approved ARAKODA®: A Game-Changer in Malaria Prevention with a $50–$70M U.S. Market Foothold ARAKODA® (tafenoquine), 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)’s flagship product, is a revolutionary antimalarial therapy that earned FDA approval in 2018 and became commercially available the following year.  Unlike other treatments, ARAKODA® provides complete protection against all stages of malaria with a convenient weekly dosing schedule—no resistance, no hassle.  Its unique attributes, including broad-spectrum activity, have earned recommendations from the CDC and cemented its reputation as the top choice for malaria prophylaxis. With a $50–$70 Mln U.S. market for malaria prevention alone, ARAKODA® has already established a foothold in a critical space, showing consistent sales growth.  And let’s not overlook the bigger picture: a global burden of 249 Mln malaria cases annually underscores the dire need for solutions like ARAKODA®. 60 Degrees Pharmaceuticals Positions Tafenoquine to Address Rising Cases of Chronic and Acute Babesiosis Building on its success in malaria, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is now tackling babesiosis, a tick-borne disease that is rapidly increasing in the U.S. The company has launched pivotal trials for acute babesiosis and plans to address chronic cases next.  FDA orphan status for tafenoquine highlights its potential as the only game in town for a disease where existing treatments lack efficacy. Babesiosis isn’t just a public health issue—it’s a market with significant potential. With up to 1 Mln chronic cases in the U.S. and growing acute incidence rates, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is positioning itself to dominate this emerging space, potentially expanding its patient reach to over 2 Mln. Strong Intellectual Property Portfolio A critical driver of 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)’s success is its robust and expanding intellectual property portfolio.  The company holds three Orange Book-listed patents for tafenoquine, protecting its malaria prevention innovations until 2035.  With 42 additional patents filed, pending, or optioned across multiple therapeutic areas—including tick-borne diseases and respiratory viruses—60P is playing a long game, ensuring market exclusivity and driving future growth. A Leadership Team That Delivers Behind this powerhouse is a leadership team with unmatched experience and credentials. CEO Geoffrey Dow is a 20-year veteran in tropical disease product development, having spearheaded the regulatory approval of ARAKODA®.  Chief Medical Officer Bryan Smith, with 30+ years of clinical expertise, brings unparalleled insight into pharmacovigilance and regulatory strategy.  And let’s not forget Chief Commercial Officer Kristen Landon, who has launched more than a dozen blockbuster brands, driving revenues well into nine figures. This team isn’t just talking the talk—they’re walking the walk, executing on ambitious plans to scale commercial operations and meet aggressive pro-fit-ability targets by Q4 2026. Evolving Strategies for Commercial Growth 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)’s commercial strategy for ARAKODA® is razor-sharp: differentiate it from generic competitors with a compelling value story, expand its use among healthcare providers, and reduce access barriers through co-pay assistance programs.  This targeted approach has already shown results, with organic sales growth reflecting increased awareness among prescribers in the Lyme disease community. And it doesn’t stop there.  The company’s forward-looking pipeline includes Celgosivir, targeting dengue and respiratory viruses, and an exploratory program for canine babesiosis, hinting at diversification into veterinary markets. Fiscal Momentum and Milestones Ahead The numbers don’t lie. Recent rounds have injected over $5.9M into 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)’s coffers, enabling critical funding in commercialization and clinical development.  With three babesiosis trials underway, the company is poised to deliver interim results by early 2026—just in time to accelerate its push toward pro-fit-ability. Upcoming potential catalysts include sales growth milestones, new product development collaborations, and regulatory submissions.  If history is any guide, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) isn’t just checking boxes; it’s carving out its place in the biotech space. The Bottom Line 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is more than a pharma company—it’s a force to be reckoned with in the fight against infectious diseases.  With groundbreaking products, a visionary leadership team, and an aggressive roadmap for growth, (SXTP) is redefining what’s possible in this space.  For those watching closely, one thing is clear: this company doesn’t just participate—it dominates. 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is drawing attention with several potential catalysts that could help drive its momentum.  With a razor-thin float of only 1.5M shares, the company is positioned for potential market movements.  Recent insider purchases by the CEO reflect confidence in its direction, while a 119% upside target points to notable growth potential. The company has also seen an approximate 182% move over the past six weeks, an indicator of growing market interest.  As of midday, yesterday 12/9, (SXTP) was triggering 16 Bullish Signals, including the momentum indicator, on TradingView’s technical analysis tool using the 5, 15, and 30 minute time-frames.  Coupled with a robust intellectual property portfolio of over 40 patents, the company is positioning itself to advance its efforts in addressing unmet medical needs.  These elements create a compelling case for keeping an eye on this emerging biotech player. 7 Reasons Why 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is Back On Our Radar This Morning… 1. Bullish Signals: Triggering 16 bullish indicators on TradingView’s technical analysis tool, pointing to strong momentum potential. 2. Insider Coverage: CEO insider purchases demonstrate a strong belief in the company’s future and commitment to growth. 3. Analyst Projection: A $3.40 target suggests a potential 119% upside from yesterday's $1.55 open. 4. Limited Float: With only 1.5M shares available, the stage is set for significant market swings if demand shifts. 5. Growing Recognition: An approximate 182% move in six weeks showcases rising awareness and interest in the market. 6. Robust IP Portfolio: Over 40 patents, including three Orange Book-listed patents, ensure innovation is well-protected and market exclusivity remains strong. 7. FDA-Approved Innovation: ARAKODA® has secured FDA approval and is now targeting the $50–$70M U.S. malaria market, with global implications. Consider Adding 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) to Your Radar This Week… 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) appears to be positioning itself as a standout in the biotech space, combining technical momentum, market potential, and innovation. With 16 bullish signals on TradingView’s analysis tool and recent CEO insider buying reinforcing leadership’s confidence, the company is attracting attention. An analyst's target suggesting a 119% potential upside and a limited float of just 1.5M shares set the stage for potential swings as interest continues to grow. The company’s approximate 182% change in six weeks highlights increasing recognition, while its robust intellectual property portfolio and FDA-approved ARAKODA® solidify its position in both the U.S. malaria market and on the global health stage. With these catalysts aligning, 60 Degrees Pharmaceuticals, Inc. is building a compelling narrative for those closely watching the biotech sector. Here’s the deal: (SXTP) has an ultra-tight float of just 1.5M shares, and an analyst is eyeing a target that screams 119% potential upside. As of midday yesterday (12/10), (SXTP) has been lighting up TradingView with 16 Bullish Signals. Keep in mind, over the last week the company’s CEO has picked up over 70,000 shares. And over the past week, (SXTP) moved approximately 157% from last Tuesday when it was in the $1.03 range.  With (SXTP)’s 200-Day moving average now at 2.2181 we need to keep a very close eye on this.  If you missed our coverage on 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) yesterday you’re in luck. Because after its approximate 70% one day move yesterday it’s back on our radar this morning. (SXTP) is back in the headlines this morning with major news on the expansion of their tafenoquine clinical trial. Keep a lookout for my next update. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired by TD Media LLC for a period beginning on 12/9/2024 and ending on 12/11/2024 to publicly disseminate information about (SXTP:US) via digital communications. Under this agreement, Headline Media LLC has been paid ten thousand USD (“Funds”) to disseminate information about (SXTP:US) via digital communications. These Funds were part of the funds that TD Media LLC received from 60 Degrees Pharmaceuticals Inc., the issuer of (SXTP:US).Neither Headline Media LLC, TD Media LLC or their members own shares of (SXTP:US). Please see important disclosure information here: https://marketcrux.com/disclosure/sxtp/

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice